FOMX Profile
Foamix Pharmaceuticals Ltd. (FOMX) is a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing foam-based formulations of drugs to address unmet needs in dermatology. The company's lead product candidate, FMX101, is a topical foam formulation of minocycline that is currently in Phase III clinical trials for the treatment of moderate-to-severe acne. Foamix is also developing a foam formulation of minocycline for the treatment of rosacea, and has several other product candidates in preclinical development.
Foamix's proprietary foam technology platform is designed to enable the efficient delivery of a wide range of drugs, including those that are poorly soluble or have low bioavailability. The company believes that its technology has the potential to improve drug efficacy, safety, and patient convenience, and may offer a competitive advantage over other topical drug delivery methods.
Headquartered in Israel, Foamix Pharmaceuticals Ltd. was founded in 2003 and is traded on the NASDAQ stock exchange under the ticker symbol FOMX.
|
